Theragenics to distribute Oncuras brachytherapy products

Manjula Puthenedam, PhD, | | Health Imaging | Oncology Imaging
Theragenics has signed a non-exclusive agreement with Oncura to distribute its brachytherapy-related products in North America.

The one-year agreement is effective May 1 and provides for additional one-year terms upon mutual agreement of the parties, said the Buford, Ga.-based Theragenics.

Oncura, a unit of GE Healthcare, manufactures, markets and sells the iodine-125 based OncoSeed used in prostate cancer treatments.

Manjula Puthenedam, PhD,

Related Content

New PET method combines antibody with radioactive isotope to improve lung cancer detection
VI-RADS threshold, imaging features predict bladder cancer invasiveness with nearly 100% accuracy
PHOTO GALLERY: thyroid nodule imaging
Tiny 'water bears' may hold key to reducing radiation-induced side effects
High-intensity focused ultrasound could allow prostate cancer patients to avoid surgery
MRI-first approach could allow many to safely forego prostate biopsy

Around the web

Radiology Business
Shift toward imaging outside the hospital could save billions

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Cardiovascular Business
‘A significant milestone’: First US patients receive doses of new PET radiotracer for CAD

Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care. 

Cardiovascular Business
Continuation of 99mTc-PYP shortage prompts need for alternative cardiac amyloidosis imaging

After three years of intermittent shortages of nuclear imaging tracer technetium-99m pyrophosphate, there are no signs of the shortage abating.